New cancer drug combo tested in patients out of options
NCT ID NCT04501276
Summary
This early-stage trial tested the safety and dosing of a new cancer drug called ADG116, both alone and combined with other immune-boosting drugs, in patients with advanced solid tumors that have spread. The study involved 72 adults whose cancer had progressed despite standard treatments. Researchers aimed to find safe dose levels and gather initial evidence about whether these drug combinations could help control tumor growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED/METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ashford Cancer Centre Research
Kurralta Park, Australia
-
Cabrini Hospital
Malvern, Australia
-
Macquarie University
Sydney, Australia
-
Next Oncology
San Antonio, Texas, 78229, United States
Conditions
Explore the condition pages connected to this study.